Savella has been expensive primarily because it had no generic competition until very recently. As the only SNRI approved specifically for fibromyalgia with its particular chemical profile, it occupied a niche market position that allowed the manufacturer to set high prices without pressure from competitors. That’s now changing, with generic milnacipran hitting the market in 2026, but for years patients faced steep costs for a drug with no cheaper equivalent.
Patent Protection Kept Generics Off the Market
The single biggest driver of Savella’s price is straightforward: patent exclusivity. Without generic alternatives, the manufacturer faced no price competition. Eight different companies filed applications to make generic versions, but FDA approval for the first generic applicant isn’t scheduled until March 2026, with the last qualifying patent not expiring until September 2029. That means Savella has enjoyed well over a decade of market exclusivity since its original approval.
This pattern is common with brand-name drugs. Once generics enter the market, prices typically drop dramatically. The good news for patients is that generic milnacipran is on the horizon, and GoodRx already lists generic milnacipran tablets at significantly lower prices than the brand: roughly $38 to $52 for a 30-day supply of 60 tablets, depending on the dose strength.
A Narrow Market With Limited Competition
Only three drugs are FDA-approved for fibromyalgia: milnacipran (Savella), duloxetine (Cymbalta), and pregabalin (Lyrica). Both Cymbalta and Lyrica have had generic versions available for years, which drove their prices down. Savella, without that generic pressure, remained the most expensive option in the category.
Milnacipran also occupies an unusual pharmacological niche. While it’s classified as an SNRI like duloxetine, it works differently. It inhibits norepinephrine reuptake about three times more potently than serotonin reuptake, which is the opposite ratio of most SNRIs. This distinction matters because norepinephrine plays a key role in pain signaling, which is why milnacipran was developed specifically for fibromyalgia rather than depression. That specialization gave the manufacturer justification to price it as a targeted therapy rather than a general antidepressant, even though the manufacturing costs aren’t dramatically different.
Insurance Often Creates Additional Hurdles
Even with insurance, Savella can be costly. On Medicare Part D formularies, it’s commonly placed on Tier 3, which means higher copays than preferred generics. Every strength of Savella, from the 12.5 mg starter dose to the 100 mg tablets, requires prior authorization before your plan will cover it. That means your doctor has to submit documentation proving you need this specific medication, often showing that you’ve already tried and failed on cheaper alternatives like generic duloxetine.
This prior authorization requirement is itself a reflection of cost. Insurers impose these extra steps specifically for expensive drugs to steer patients toward cheaper options first. If your prior authorization is denied, the out-of-pocket cost can be substantial.
How Savella Compares on Cost-Effectiveness
Cost-effectiveness research paints a mixed picture for Savella. When researchers compared the major fibromyalgia drugs head to head, using the older antidepressant amitriptyline as a reference point, amitriptyline came out both more effective and less expensive than milnacipran. Duloxetine (generic Cymbalta) was the preferred strategy overall, offering greater net benefit than milnacipran at a lower price point.
This doesn’t mean Savella doesn’t work. For some patients, its norepinephrine-heavy mechanism provides relief when other medications haven’t. But from a pure value standpoint, it’s hard to justify the price premium when cheaper alternatives perform as well or better for most people. That’s part of why insurers push back on coverage and why many doctors try duloxetine or pregabalin first.
Ways to Reduce What You Pay
If Savella is the medication that works for you, there are several ways to lower the cost. Manufacturer savings programs through AbbVie may be available, though eligibility criteria vary. Pharmacy discount cards from services like GoodRx can significantly reduce the cash price, especially as generic milnacipran becomes available. Some patients also find that independent patient assistance foundations cover specialty copays for fibromyalgia medications.
If you’re paying out of pocket and the cost is prohibitive, it’s worth asking your prescriber whether generic duloxetine or another alternative might work for your situation. For patients who’ve already tried those options without success, documenting that history strengthens the case for insurance approval and prior authorization of Savella. Keep records of which medications you’ve tried, how long you were on each one, and why they were discontinued.